A possible favorable effect of colchicine in IgA nephropathy in a carrier of a MEFV mutation.
IgA nephropathy is the most common primary glomerulopathy. Currently, no satisfactory treatment is available and as a result, a significant proportion of affected patients progress to end-stage renal disease. We present a patient with IgA nephropathy in whom continuous colchicine treatment induced remission, which has lasted for 22 years. The patient was a carrier of a mutation in the FMF gene (MEFV). This case raises hopes for a better prognosis in at least one subgroup of IgA nephropathy, consisting of patients who happen to be heterozygous carriers of MEFV mutations.
Koukoui
L
L
Department of Medicine F, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Blau
A
A
Kopolovic
J
J
Pras
M
M
Livneh
A
A
D000328:Adult; D003078:Colchicine / Q000627:therapeutic use*; D010505:Familial Mediterranean Fever / Q000235:genetics*; D005922:Glomerulonephritis, IGA / Q000188:drug therapy* / Q000235:genetics*; D006579:Heterozygote; D006801:Humans; D008297:Male; D009154:Mutation
D003078:Colchicine